Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $1.11 in the prior trading day, Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) closed at $0.91, down -18.03%. In other words, the price has decreased by -$18.03 from its previous closing price. On the day, 5.98 million shares were traded. BCLI stock price reached its highest trading level at $1.11 during the session, while it also had its lowest trading level at $0.81.
Ratios:
Our goal is to gain a better understanding of BCLI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.04 and its Current Ratio is at 0.04.
Maxim Group reiterated its Buy rating for the stock on December 19, 2016, while the target price for the stock was revised from $5 to $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 01 ’24 when Lebovits Chaim bought 1,836 shares for $3.43 per share. The transaction valued at 6,292 led to the insider holds 80,960 shares of the business.
Lebovits Chaim bought 22,000 shares of BCLI for $5,016 on Sep 30 ’24. The President & CEO now owns 1,186,865 shares after completing the transaction at $0.23 per share. On Jul 19 ’24, another insider, Dagher Ibrahim B., who serves as the Chief Medical Officer of the company, sold 63,000 shares for $0.35 each. As a result, the insider received 22,069 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCLI now has a Market Capitalization of 5610498 and an Enterprise Value of 7859317.
Stock Price History:
The Beta on a monthly basis for BCLI is 0.38, which has changed by -0.8954023 over the last 52 weeks, in comparison to a change of 0.028231144 over the same period for the S&P500. Over the past 52 weeks, BCLI has reached a high of $10.05, while it has fallen to a 52-week low of $1.00. The 50-Day Moving Average of the stock is -40.98%, while the 200-Day Moving Average is calculated to be -67.24%.
Shares Statistics:
The stock has traded on average 41.16K shares per day over the past 3-months and 637110 shares per day over the last 10 days, according to various share statistics. A total of 6.14M shares are outstanding, with a floating share count of 5.07M. Insiders hold about 22.32% of the company’s shares, while institutions hold 6.33% stake in the company. Shares short for BCLI as of 1741910400 were 122765 with a Short Ratio of 3.33, compared to 1739491200 on 110846. Therefore, it implies a Short% of Shares Outstanding of 122765 and a Short% of Float of 2.27.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Brainstorm Cell Therapeutics, Inc (BCLI) is presently subject to a detailed evaluation by 1 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.44 and low estimates of -$0.44.
Analysts are recommending an EPS of between -$2.21 and -$2.21 for the fiscal current year, implying an average EPS of -$2.21. EPS for the following year is -$1.47, with 2.0 analysts recommending between -$0.98 and -$1.95.
